(Q53272521)

12 May 2018

title

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. (English)

1 reference

12 May 2018

metabolic dysfunction–associated steatotic liver disease

1 reference

1 reference

1 reference

2

Matthew J Budoff

1 reference

12 May 2018

Sammy Saab

3

object named as

Sammy Saab

1 reference

12 May 2018

author name string

Temitope Foster

1

1 reference

12 May 2018

Naser Ahmadi

4

1 reference

12 May 2018

Craig Gordon

5

1 reference

12 May 2018

Alan D Guerci

6

1 reference

12 May 2018

language of work or name

English

0 references

publication date

14 September 2010

1 reference

12 May 2018

The American Journal of Gastroenterology

published in

1 reference

12 May 2018

volume

106

1 reference

12 May 2018

issue

1

1 reference

12 May 2018

page(s)

71-77

1 reference

12 May 2018

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

The natural history of nonalcoholic fatty liver disease: a clinical histopathological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Review article: the metabolic syndrome and non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Current treatment strategies for non-alcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Noninvasive assessment of hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Statins and liver toxicity: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Statins in liver disease: a molehill, an iceberg, or neither?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.299

21 January 2018

Identifiers

DOI

10.1038/AJG.2010.299

1 reference

12 May 2018

PubMed ID

20842109

1 reference

12 May 2018